KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Raw Materials (2018 - 2020)

Historic Raw Materials for Amneal Pharmaceuticals (AMRX) over the last 3 years, with Q1 2020 value amounting to $162.7 million.

  • Amneal Pharmaceuticals' Raw Materials changed N/A to $162.7 million in Q1 2020 from the same period last year, while for Mar 2020 it was $162.7 million, marking a year-over-year change of. This contributed to the annual value of $172.2 million for FY2019, which is 522.7% down from last year.
  • As of Q1 2020, Amneal Pharmaceuticals' Raw Materials stood at $162.7 million.
  • In the past 5 years, Amneal Pharmaceuticals' Raw Materials registered a high of $182.8 million during Q3 2019, and its lowest value of $162.7 million during Q1 2020.
  • Over the past 3 years, Amneal Pharmaceuticals' median Raw Materials value was $176.9 million (recorded in 2018), while the average stood at $174.8 million.
  • Within the past 5 years, the most significant YoY rise in Amneal Pharmaceuticals' Raw Materials was 522.7% (2019), while the steepest drop was 522.7% (2019).
  • Quarter analysis of 3 years shows Amneal Pharmaceuticals' Raw Materials stood at $181.7 million in 2018, then dropped by 5.23% to $172.2 million in 2019, then dropped by 5.48% to $162.7 million in 2020.
  • Its Raw Materials was $162.7 million in Q1 2020, compared to $172.2 million in Q4 2019 and $182.8 million in Q3 2019.